Circulating tumor DNA dynamics predict response and outcomes in early-stage non-small cell lung cancer treated with neoadjuvant chemoimmunotherapy.
Blood tests measuring tumor DNA changes during treatment can predict which lung cancer patients will benefit from chemoimmunotherapy.
This study demonstrates that changes in circulating tumor DNA levels during neoadjuvant treatment can predict which early-stage lung cancer patients will respond to chemoimmunotherapy. The findings support ctDNA as a real-time, non-invasive biomarker for treatment response monitoring.
What the study was
- Study design
- Prospective cohort / correlative analysis
- Population
- Early-stage NSCLC patients receiving neoadjuvant chemoimmunotherapy
- Category
- Early Detection
- Maturity
- Validated
Why it surfaced
ctDNA for treatment response monitoring in early-stage NSCLC is a high-signal topic directly aligned with the liquid biopsy/early detection watchlist. Prospective study design adds credibility. Near-term clinical implementability.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.